16:00 – 16:30 – Cancer Immunotherapy, a success story – Prof. Dr. Christoph Zielinski
16:30 – 17:00 – Gene engineering of the immune system: the dawn of a new era – Adrian Bot MD. Ph.D.
17:00 – 17:30 – Novel strategies to prime and sustain the cancer-immunity cycle in immunologically cold tumors – Prof. Caius G. Radu
17:30 – 18:00 – Break
18:00 – 18:30 – Simpozion educational Novartis – Therapeutic progress of CDK4/6 inhibitors in locally advanced or metastatic HR+/ HER2- Breast Cancer – Dr. Dragoș Median
18:30 – 19:00 – Simpozion AstraZeneca – New state of the art in SCLC and NSCLC – Dr. Mircea Dediu
19:00 – 19:30 – Do all patients with NSCLC need immune-therapy at some point
- Yes – Dr. Andrei Ungureanu
- No – Dr. Mircea Dediu
19:30 – 20:00 – Status of radiation therapy in postoperative setting for NSCLC – Prof. Dr. Rodica Anghel
16:00 – 16:30 – Should we evaluate the PDL – 1 status in deciding the first line immunotherapy in gastric cancer? – Prof. Dr. Gerald Prager
16:30 – 17:00 – Hepatobiliary cancer treatment – Asist. Univ. Dr. Luiza Șerbănescu
17:00 – 17:30 – Neoadjuvant versus adjuvant therapy in advanced rectal cancer – Conf. Dr. Laura Rebegea
17:30 – 18:00 – Break
18:20 – 18:40 -Title: Supporting high-quality radiotherapy for everyone Tom Wilson, Sr Manager, Product Marketing HW. Varian, a Siemens Healthineers company.
18:40 – 19:00 – Simpozion AstraZeneca – Enhertu – Extend HER2+ expectations – Conf. Dr. Laurenția Galeș
19:00 – 19:30 – Current landscape in HER2 + metastatic breast cancer– Dr. Alexandru Eniu
19:30 – 20:00 – How to use genetic tests in tailoring adjuvant treatment in breast cancer – Prof. Dr. Rupert Bartsch
20:00 – 20:30 – Current status in postmastectomy radiation therapy – Dr. Valeria Masiello
15:30 – 16:00 – Update in advanced loco-regional cervical cancer treatment – Dr. Claudia Ordeanu
16:00 – 16:30 – Simpozion Educational Janssen – What Influences Treatment Choices in mHSPC – beyond efficacy endpoints – Conf. Dr. Laurenția Galeș
16:30 – 17:00 – Update in the radiotherapy for prostate cancer – Prof. Dr. Gabriel Kacso
17:00 – 17:30 – What is the best partner for ADT in first line mHSPC – Conf. Dr. Laurenția Galeș
17:30 – 18:00 – Break
18:00 – 18:20 – Xtandi Win Time – Sesiune sustinuta cu sprijinul Astellas
18:20 – 18:40 – Simpozion AstraZeneca – Lynparza in prostate cancer. Dare to challenge. – Prof. Dr. Rodica Anghel
18:40 – 19:00 – Simpozion AstraZeneca – Lynparza in advanced ovarian cancer. Dare to dream. – Dr. Oana Trifănescu
19:00 – 19:30 – Update of the current indication for first line therapy in BRAF positive metastatic melanoma– Prof. Dirk Schadendorf
19:30 – 20:00 – Non-melanoma skin cancer – update – Dr. Oana Trifănescu
20:00 – 20:30 – Simpozion Educational – Melanom – Sustinut cu Sprijinul Novartis Romania
– Updates in adjuvant treatment of BRAF+ melanoma – Prof. Dr. Dirk Schadendorf
20:30 – 21:00 – Optimal treatment of brain metastases in malignant melanoma – Dr. Radu Mitrică
16:00 – 16:30 – Curative RT in Head & Neck – Prof. Dr. Strojan Primoz
16:30 – 17:05 – Simpozion MSD – Changing the Treatment Paradigm of r/M HNSCC with Keytruda in the First Line – Prof. Dr. Cornelia Nițipir
17:05 – 17:35 – How to choose the optimal first line treatment in mRCC – Prof. Dr. M. Schmidinger
17:35 – 18:05 – Metastatic urothelial bladder cancer – update – Prof. Dr. Jinga Viorel
18:05 – 18:35: Break
18:35 – 19:05 – CNS – Heavy ions, carbo ions, proton therapy – RT – Dr. Mihai Georgescu
19:05 – 19:35 – Sarcoma – Bone, soft tissue and GIST – Prof. Dr. Thomas Brodowicz